In this episode, Martin lays out his bearish thesis on Kodiak Sciences and explains the factors driving his cautious outlook on the biotech company. He examines its clinical pipeline, trial data, competitive landscape, regulatory considerations, and valuation, discussing the risks and catalysts he believes investors should consider when evaluating the stock.
Podden och tillhörande omslagsbild på den här sidan tillhör
Urban Tapes. Innehållet i podden är skapat av Urban Tapes och inte av,
eller tillsammans med, Poddtoppen.
